SCHEDULE: Migdal Insurance Discloses 5.37% Stake in Teva Pharma

Migdal Insurance & Financial Holdings Ltd. has reported a beneficial ownership of 5.37% in Teva Pharmaceutical Industries Ltd. as of December 31, 2025.

Summary

• Migdal Insurance & Financial Holdings Ltd. and its various direct or indirect, majority or wholly-owned subsidiaries beneficially own 61,689,363 ordinary shares of Teva Pharmaceutical Industries Ltd.
• This ownership represents 5.37% of Teva's total ordinary shares outstanding, based on 1,149,812,898 shares outstanding as of December 31, 2025.
• The beneficial ownership is distributed among subsidiaries, with Migdal Sal Domestic Equities holding 4.69% (53,935,231 shares), Migdal Mutual Funds Ltd. holding 0.67% (7,647,132 shares), and Migdal Insurance Company Ltd. holding 0.01% (107,000 shares) as of January 20, 2026.
• Each of Migdal's subsidiaries operates under independent management and makes its own independent voting and investment decisions.
• The securities were not acquired or held for the purpose of changing or influencing the control of Teva Pharmaceutical Industries Ltd.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a reputable institutional investor like Migdal suggests confidence in Teva's value proposition and future prospects, without indicating any immediate control-related issues.

Positives

• A significant institutional investor, Migdal Insurance & Financial Holdings Ltd., has taken a substantial 5.37% stake in Teva Pharmaceutical Industries Ltd., indicating confidence in the company's long-term prospects.
• The diversified nature of Migdal's holdings across its various subsidiaries (insurance, equities, mutual funds) suggests a broad institutional interest in Teva.

Negatives

• No specific negative information regarding Teva Pharmaceutical Industries Ltd. is disclosed in this beneficial ownership report.

Risks

• No specific risks related to Teva Pharmaceutical Industries Ltd. are mentioned in this beneficial ownership report, as it primarily concerns the reporting person's ownership disclosure.

Future Outlook

NA

Management Comments

• The securities reported herein are beneficially owned by various direct or indirect, majority or wholly-owned subsidiaries of Migdal Insurance & Financial Holdings Ltd. (the "Subsidiaries"), such as Migdal Insurance Company Ltd., Migdal Sal Domestic Equities, Migdal Makefet Pension & Provident Funds Ltd., and Migdal Mutual Funds Ltd..
• Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that a significant stake by a major institutional investor like Migdal Insurance & Financial Holdings Ltd. in a pharmaceutical company such as Teva can signal a vote of confidence in the company's long-term strategy, product pipeline, or market position. This type of disclosure often attracts attention from other institutional investors and can be interpreted as a positive indicator for the stock, especially in the competitive and capital-intensive pharmaceutical sector.

Comparison to Industry Standards

• Institutional ownership levels vary widely across industries and company sizes. For a large-cap pharmaceutical company like Teva, a 5.37% stake by a single institutional group is a notable position, though not uncommon.
• For example, other major pharmaceutical companies often see significant institutional ownership, with top institutional holders frequently holding stakes ranging from 3% to over 10%. This level of ownership by Migdal is consistent with a substantial, but not controlling, institutional investment.
• Compared to activist investors who might take similar stakes to influence management, Migdal's certification explicitly states the investment is not for control, aligning with typical passive institutional investment strategies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially attract further institutional interest, which could positively influence share price stability and liquidity.
• Management: While Migdal certifies it is not seeking to influence control, a large institutional holder can still exert influence through voting and engagement, encouraging management to maintain strong performance and governance.

Key Dates

Recommendation

The filing indicates a significant institutional investor has taken a substantial stake in Teva, which is generally a positive signal of confidence. However, as a Schedule 13G, it does not provide new operational or financial performance data for Teva. Therefore, while the institutional interest is noteworthy, it primarily reinforces a 'hold' position for existing investors, suggesting continued monitoring of Teva's underlying business fundamentals rather than an immediate 'buy' or 'sell' trigger based solely on this ownership disclosure.

Keywords

Teva Pharmaceutical Industries, Migdal Insurance, Beneficial Ownership, Schedule 13G, Pharmaceuticals, Institutional Investment, Ordinary Shares, Israel